Physician profile
Justin Brown
NPI 1134358005
$141,902.46
in general payments reported to CMS, 2019-2025
49 companies · $70K in 2025
The $70K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19K · 2022: $29K · 2023: $4,097 · 2024: $20K · 2025: $70K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $61K · Travel and Lodging: $15K · Food and Beverage: $11K · Honoraria: $7,261 · Education: $55.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $61,406.25 |
| Travel and Lodging | $14,533.36 |
| Food and Beverage | $10,580.59 |
| Honoraria | $7,261.00 |
| Education | $55.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $86,413.41 | 2021-2025 | Korlym |
| Novo Nordisk INC | $40,970.70 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $5,446.80 | 2021-2024 | Farxiga |
| Lilly USA, LLC | $1,088.54 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $768.62 | 2021-2025 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $734.64 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $573.10 | 2021-2025 | Jardiance |
| Recordati_rare_diseases_inc. | $540.27 | 2021-2025 | Isturisa, Signifor Lar |
| Medtronic, INC. | $510.45 | 2021-2025 | Inpen Smart Insulin Delivery System, Intellis Adaptivestim |
| Dexcom, INC. | $424.29 | 2021-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Mannkind Corporation | $407.35 | 2021-2023 | Afrezza |
| Sanofi-Aventis U.S. LLC | $399.76 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $372.17 | 2022-2025 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $315.27 | 2021-2024 | |
| Abbvie INC. | $272.88 | 2022-2025 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $272.00 | 2021-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $258.61 | 2021-2022 | |
| Antares Pharma, INC. | $182.01 | 2021-2024 | Xyosted, Nocdurna, Tlando |
| Novartis Pharmaceuticals Corporation | $160.40 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $144.02 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Nestle Healthcare Nutrition INC. | $120.55 | 2021-2022 | |
| Ascensia Diabetes Care US INC. | $119.98 | 2022-2024 | |
| Amgen INC. | $118.13 | 2021-2025 | Evenity, Repatha, Tepezza |
| Amneal Pharmaceuticals LLC | $102.25 | 2021-2024 | Unithroid |
| Neurocrine Biosciences, INC. | $98.26 | 2025 | |
| Sequel Med Tech, LLC | $96.57 | 2025 | Twiist |
| Radius Health, INC. | $94.30 | 2023-2024 | Tymlos |
| Eusa Pharma (US) LLC | $82.63 | 2022 | |
| Esperion Therapeutics, INC. | $80.24 | 2021-2025 | Nexletol |
| Ibsa Pharma INC. | $73.08 | 2021-2023 | Tirosint, Licart |
| Amryt Pharma Holdings LTD | $72.11 | 2022-2023 | Mycapssa |
| Lexicon Pharmaceuticals, INC. | $68.51 | 2023-2024 | Inpefa |
| Beta Bionics, INC. | $61.55 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Madrigal Pharmaceuticals | $59.05 | 2025 | Rezdiffra |
| Amarin Pharma, INC. | $52.81 | 2021-2022 | |
| Cequr Corporation | $50.62 | 2023-2025 | Cequr Simplicity |
| Grt US Holding, INC. | $40.77 | 2022 | |
| Lifescan, INC. | $37.37 | 2021-2023 | |
| Pfizer INC. | $29.43 | 2021-2024 | |
| Zealand Pharma US, INC. | $25.31 | 2021 | |
| Averitas Pharma INC. | $20.85 | 2025 | Qutenza |
| Kyowa Kirin, INC. | $20.28 | 2025 | |
| Halozyme INC | $20.25 | 2023 | |
| Alvogen INC | $20.01 | 2025 | Teriparatide |
| Chiesi USA, INC. | $19.91 | 2025 | Mycapssa |
| Ultragenyx Pharmaceutical INC. | $17.00 | 2021 | |
| Tolmar, INC. | $16.09 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $15.51 | 2022 | |
| Clarus Therapeutics INC. | $13.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.